12:00 AM
 | 
Feb 14, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Enbrel etanercept: Phase IV data

A double-blind, North American Phase IV trial in 54 evaluable patients with moderate to severe plaque psoriasis with scalp involvement showed that twice-weekly 50 mg Enbrel for 12 weeks followed by once-weekly 50 mg Enbrel for an additional 12 weeks met the primary endpoint of significantly improving mean PSSI score from baseline to week 12 vs. placebo for 12 weeks followed by twice-weekly 50 mg Enbrel for an...

Read the full 317 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >